Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

Clinical Infectious Diseases

Volumn 67, Issue 5, 2018, Pages 649-656

  Gerding, Dale N ^a   Kelly, Ciaran P ^b   Rahav, Galia ^c   Lee, Christine ^d,e   Dubberke, Erik R ^f   Kumar, Princy N ^g   Yacyshyn, Bruce ^h   Kao, Dina ⁱ   Eves, Karen ^j   Ellison, Misoo C ^k   Hanson, Mary E ^l   Guris, Dalya ^j   Dorr, Mary Beth ^j  

^a HINES VA HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j Clinical Research   (United States)

^k Late Development Statistics Biostatistics   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

bezlotoxumab.; C. difficile infection; CDI; recurrence

Indexed keywords

BEZLOTOXUMAB; FIDAXOMICIN; PLACEBO; VANCOMYCIN; ANTIINFECTIVE AGENT; METRONIDAZOLE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ADVERSE OUTCOME; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHARLSON COMORBIDITY INDEX; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; FECES MICROFLORA; FEMALE; FOLLOW UP; HOSPITAL MORTALITY; HUMAN; HYPOALBUMINEMIA; INFECTION PREVENTION; INFECTION RISK; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; VERY ELDERLY; ADOLESCENT; AGE; CLINICAL TRIAL; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; DRUG EFFECT; FECAL MICROBIOTA TRANSPLANTATION; HOSPITAL READMISSION; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RISK FACTOR; SECONDARY PREVENTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FIDAXOMICIN; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PATIENT READMISSION; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; VANCOMYCIN; YOUNG ADULT;

EID: 85049058923     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy171     Document Type: Article

References (23)

1. Lagier J. Gut microbiota and Clostridium difficile infections. Hum Microbiome J 2016; 2:10-4.
2. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
3. Johnson S, Louie TJ, Gerding DN, et al; Polymer Alternative for CDI Treatment (PACT) Investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345-54.
4. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis 2016; 62:574-80.
5. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
6. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-703.
7. Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011; 53:1173-8.
8. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection Clin Microbiol Infect 2012; 18(Suppl 6):21-7.
9. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
10. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014; 9:e98400.
11. Inns T, Gorton R, Berrington A, et al. Effect of ribotype on all-cause mortality following Clostridium difficile infection. J Hosp Infect 2013; 84:235-41.
12. See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58:1394-400.
13. Ma GK, Brensinger CM, Wu Q, JD L. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017; 167:152-8.
14. Wilcox MH, Gerding DN, Poxton IR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376:305-17.
15. Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015; 36:452-60.
16. Prabhu VS, Cornely OA, Golan Y, et al. Thirty-day readmissions in hospitalized patients who received bezlotoxumab with antibacterial drug treatment for Clostridium difficile infection. Clin Infect Dis 2017; 65:1218-21.
17. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26.
18. Bauer MP, Notermans DW, van Benthem BH, et al; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73.
19. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:954-9.
20. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:345-51.
21. Piacenti FJ, Leuthner KD. Antimicrobial stewardship and Clostridium difficile-associated diarrhea. J Pharm Pract 2013; 26:506-13.
22. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
23. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect 2015; 21:164-70.